Figure 1.
Wästerlid et al (2024),6 Sankey diagram showing the distribution and re-distribution of systemic treatment types across treatment lines 1, 2, 3, and 4 among patients diagnosed with follicular lymphoma (FL) 2007–2014, followed through 2020 in Sweden. BR, bendamustine rituximab; CVP, cyclophosphamide, vincristine, prednisone; R-FC, rituximab, fludarabine, and cyclophosphamide.